TUBB4A Inhibits Glioma Development by Regulating ROS-PINK1/Parkin-Mitophagy Pathway-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

TUBB4A Inhibits Glioma Development by Regulating ROS-PINK1/Parkin-Mitophagy Pathway

Published:2024-09-04 Issue: Volume: Page:
ISSN:0893-7648
Container-title:Molecular Neurobiology
language:en
Short-container-title:Mol Neurobiol

Author:

Xi Xueru,Chen Suqin,Zhao Xiaoli,Zhou Zimu,Zhu Shanjie,Ren Xurui,Wang Xiaomei,Wu Jing,Mu Shuai,Li Xianwen^ORCID,Shan Enfang,Cui Yan

Funder

Research Project of Philosophy and Social Science in Universities and Colleges of Jiangsu Province

Jiangsu Commission of Health

Connotation Construction Project of Nanjing Medical University for Priority Academic of Nursing Science

Natural Science Foundation of Jiangsu Province

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12035-024-04459-z.pdf

Reference53 articles.

1. Yang K, Wu Z, Zhang H, Zhang N, Wu W, Wang Z, Dai Z, Zhang X et al (2022) Glioma targeted therapy: insight into future of molecular approaches. Mol Cancer 21(1):39. https://doi.org/10.1186/s12943-022-01513-z

2. Nicholson JG, Fine HA (2021) Diffuse glioma heterogeneity and its therapeutic implications. Cancer Discov 11(3):575–590. https://doi.org/10.1158/2159-8290.CD-20-1474

3. Zhang Y, Xiao Y, Li G-C, Gong F-Y, Zhang X-N, Hou K (2022) Long non-coding RNAs as epigenetic mediator and predictor of glioma progression, invasiveness, and prognosis. Semin Cancer Biol 83:536–542. https://doi.org/10.1016/j.semcancer.2020.08.016

4. Lang F, Liu Y, Chou F-J, Yang C (2021) Genotoxic therapy and resistance mechanism in gliomas. Pharmacol Ther 228:107922. https://doi.org/10.1016/j.pharmthera.2021.107922

5. Xu S, Tang L, Li X, Fan F, Liu Z (2020) Immunotherapy for glioma: current management and future application. Cancer Lett 476:1–12. https://doi.org/10.1016/j.canlet.2020.02.002

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3